⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111507 | 0.81 | SCN9A (0.44) | — | |
| SCHEMBL1415469 | 0.81 | ALDH1A1 (0.57) | — | |
| SCHEMBL7029492 | 0.78 | POLB (0.42) | — | |
| SCHEMBL8958798 | 0.78 | SCN9A (0.33) | — | |
| SCHEMBL9586277 | 0.78 | CYP3A4 (0.33) | — | |
| SCHEMBL6223037 | 0.78 | TSHR (0.38) | — | |
| SCHEMBL12701660 | 0.77 | LRRK2 (0.37) | — | |
| SCHEMBL1475163 | 0.77 | GAA (0.42) | — | |
| SCHEMBL22576627 | 0.77 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL1276121 | 0.75 | APP (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | disclosed |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-12319679-B2 | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| CN-101305010-A | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2008-11-12 | — | — | CN | disclosed |
| CN-101287714-A | Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist | AVENTIS PHARMA INC (US) | 2008-10-15 | — | — | CN | disclosed |
| CN-101039920-A | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | AVENTIS PHARMA INC (US) | 2007-09-19 | — | — | CN | disclosed |
| EP-1745033-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110416-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| CN-1105108-C | Process for preparation of pyrimidine compounds | ZENECA LTD (GB) | 2003-04-09 | — | — | CN | disclosed |
| CN-1351497-A | Aminopyrimidines as sorbitol dehydrogenase inhibitors | PFIZER PROD INC (US) | 2002-05-29 | — | — | CN | disclosed |
| CN-1228086-A | Process for preparing pyrimidine compounds | ZENECA LTD (GB) | 1999-09-08 | — | — | CN | disclosed |